REALLOYS INC.

Rule 10b5-1 Trading Arrangement. None of the Company’s officers or directors adopted, modified orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended June 30, 2026, as such terms are defined under Item 408(a) of Regulation S-K.

Chief Operating Officer Employment Agreement. On August 10, 2026, REalloys Canada Inc., a wholly owned subsidiary of the Company, entered into an Employment Agreement (the “COO Employment Agreement”) with Dr. Muhammad Imran, age 52, pursuant to which Dr. Imran will serve as Chief Operating Officer of REalloys Inc. and its consolidated subsidiaries and operations, effective September 1, 2026. Dr. Imran will report to the Chief Executive Officer.

Dr. Imran joins the Company from the Saskatchewan Research Council (“SRC”), the Company’s strategic processing and metallization partner, where he most recently served as Chief Technology Officer and Vice President from January 2026 to August 2026, leading the commercialization, scale-up, and strategic deployment of advanced rare earth element processing, including technologies for NdPr and heavy rare earth elements such as dysprosium and terbium. Prior to that role, Dr. Imran served as Vice President at SRC from October 2020 to December 2025, where he led the development of commercial-scale rare earth capabilities, including technology development, engineering design, pilot-scale demonstration, equipment development, construction and commissioning, and intellectual property development. Dr. Imran holds a Ph.D. in Chemical Engineering, with a professional focus on the rare earth sector. There are no family relationships between Dr. Imran and any director or executive officer of the Company, no transactions between Dr. Imran and the Company that would require disclosure under Item 404(a) of Regulation S-K, and no arrangement or understanding between Dr. Imran and any other person pursuant to which he was selected as Chief Operating Officer.

Under the COO Employment Agreement, Dr. Imran will receive: (i) an annual base salary of $475,000; (ii) eligibility for a short-term incentive with a target of 65% of base salary; (iii) eligibility for annual long-term incentive equity awards under the 2025 Plan with a target value of 125% of base salary, commencing in the first full fiscal year following the effective date; (iv) a one-time sign-on bonus of $1,000,000, subject to a 36-month pro-rated repayment obligation in the event of a voluntary resignation without Good Reason or termination for Cause; and (v) a one-time new-hire equity grant under the 2025 Plan with a target value of $100,000, vesting in three equal annual installments.

In the event of a termination without Cause or resignation for Good Reason, Dr. Imran is entitled to severance equal to 18 months of base salary, a pro-rated short-term incentive for the year of termination, and continued vesting of 50% of unvested time-based equity awards over the 18-month severance period. In the event of a termination without Cause or resignation for Good Reason within 12 months following a Change of Control, Dr. Imran is entitled to a lump-sum payment equal to 24 months of base salary plus one times the short-term incentive target, and full acceleration of all outstanding equity awards. The COO Employment Agreement also contains customary confidentiality, 12-month non-competition and non-solicitation, and intellectual property assignment provisions. The COO Employment Agreement is governed by the laws of the Province of Saskatchewan, Canada.

The foregoing summary of the COO Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the COO Employment Agreement, which is filed as Exhibit 10.3 to this Quarterly Report on Form 10-Q and incorporated herein by reference.